T24 antigen for immunodiagnosis of Taenia solium cysticercosis
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsKathy Hancock, Fatima Williams Whitfield, Melinda L. Yushak, Sowmya Pattabhi, Victor C. W. Tsang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.
Claims29
A purified peptide comprising at least 98% sequence identity to SEQ ID NO:
- 2, and comprising amino acids 104-195 of SEQ ID NO:2, wherein the purified peptide binds to anti-T24-T.solium antibodies, and wherein the purified peptide has a purity of at least 60% by weight.
Dependencies are inferred from the claim text.